Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
US9254299B2 · kind B2 · utility
1Cited by
5References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 2012 |
| Grant date | Feb 9, 2016 |
| Priority date | — |
| Expiry date | Dec 20, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cancer can be treated by administration of TH-302 in combination with a Chk1 inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.